Breast Cancer: Clinical Trials

2,189 trials for Breast Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1004 completed, 317 terminated, 306 unknown, 249 recruiting. 2189 Phase 2, 378 Phase 1, 76 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22189Completed 1004, Terminated 317, Unknown 306, Recruiting 249, Active not recruiting 133, Withdrawn 90, Not yet recruiting 85, Suspended 4, Enrolling by invitation 1
Phase 1378Completed 162, Terminated 61, Recruiting 43, Unknown 42, Active not recruiting 25, Withdrawn 25, Not yet recruiting 19, Suspended 1
Phase 376Completed 28, Unknown 21, Terminated 9, Recruiting 8, Active not recruiting 5, Withdrawn 3, Not yet recruiting 2

Follow Breast Cancer: new trials by email Literature Review of Breast Cancer trials Research Report on Breast Cancer

Trials (filtered) newest first · largest first

All 2,189 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Multi-4SCAR-T Therapy Targeting Breast Cancer
4SCAR T cells - Breast Cancer
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute1002027-06-012026-11-02
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
Neoadjuvant Chemotherapy, Radiation Therapy, MRI - Breast Cancer, HER2-positive Breast Cancer
Phase 1 / Phase 2Not yet recruitingOhio State University Comprehensive Cancer Center842027-01-152026-11-09
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
LG00313112 - Ovarian Cancer, Small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingLG Chem2502026-12-012026-08-07
Evaluation of the Effect of Amantadine in the Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients
Amantadine (oral) - Breast Cancer, Peripheral Neuropathy Due to Chemotherapy
Phase 2Not yet recruitingAl-Azhar University802026-12-012026-10-22
EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction)
Empagliflozin - Breast Cancer, Supportive Care in Cancer
Phase 2Not yet recruitingVirginia Commonwealth University102026-12-012026-11-09
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
Pembrolizumab, Radiotherapy, Axatilimab - TNBC - Triple-Negative Breast Cancer, Breast Cancer
Phase 2RecruitingStephen Shiao342026-12-012026-11-16
Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer
Dexamethasone, Famotidine, Diphenhydramine - Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC)
Phase 2Not yet recruitingWashington University School of Medicine172026-11-302026-11-03
Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer
Trastuzumab deruxtecan, Lovastatin - Breast Cancer, Advanced Breast Cancer
Phase 2Not yet recruitingWashington University School of Medicine602026-11-302026-11-02
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
Inavolisib, Fulvestrant, Palbociclib - Breast Cancer, Diabetes Type II
Phase 2RecruitingHoffmann-La Roche402026-11-302026-11-13
Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment
Thymalfasin - Breast Cancer, TNBC - Triple-Negative Breast Cancer
Phase 2Not yet recruitingFudan University5722026-11-082026-10-20
Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
Trilaciclib, Eribulin - Breast Cancer
Phase 2Not yet recruitingSun Yat-sen University292026-11-042025-12-01
Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy
Netupitant and Palonosetron, Dexamethasone, Olanzapine 5 Mg ORAL TABLET - Breast Cancer
Phase 2Not yet recruitingFudan University842026-11-022026-11-05
DiEtary Mimicry by Glucocorticoid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Efficacy and Response (DEMETER Trial)
Dexamethasone (Oral) - Breast Cancer
Phase 2Not yet recruitingThe Netherlands Cancer Institute802026-11-012026-08-25
Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast Tumors
Mini rTG OMEGA-3 Fish Oil - Breast Cancer
Phase 2Not yet recruitingMedical College of Wisconsin352026-11-012026-10-20
A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation Therapy After Mastectomy
Mometasone Furoate 1% Cream, Mepitel Film, Intranasal mupirocin - Breast Cancer, Breast Cancer Female
Phase 2RecruitingMemorial Sloan Kettering Cancer Center1382026-10-302026-11-05
Single FrAction Interstitial BreaSt BracHytherApy
Partial Breast Irradiation - Breast Cancer
Phase 2RecruitingVirginia Commonwealth University1342026-10-192026-10-23
Pilot Study of Hydroxychloroquine for the Treatment of AIMSS
Hydroxychloroquine Sulfate (HCQ) - Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
Phase 2RecruitingIndiana University352026-10-192026-11-10
Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches
Liquid biopsy next generation sequencing - Breast Cancer, Metastatic Breast Cancer
Phase 2Not yet recruitingUniversity College Cork502026-10-102026-10-26
A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd
Trastuzumab Deruxtecan (T-DXd), Pyrotinib - Breast Cancer
Phase 2Not yet recruitingFujian Medical University282026-10-102026-09-23
Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)
Taletrectinib - Breast Cancer, Metastatic Breast Cancer
Phase 2SuspendedMegan Kruse, MD612026-10-012026-06-05

Showing 20 of 2189. Sign in to see all of them.

Narrower conditions

Breast Neoplasms (2189)  ·  Triple Negative Breast Neoplasms (112)  ·  Neoplasm Metastasis (111)  ·  Ovarian Neoplasms (92)  ·  Breast Neoplasms, Male (82)  ·  Neoplasms (76)  ·  Lung Neoplasms (73)  ·  Carcinoma, Non-Small-Cell Lung (62)  ·  Colorectal Neoplasms (58)  ·  Prostatic Neoplasms (56)  ·  Pancreatic Neoplasms (50)  ·  Melanoma (41)  ·  Brain Neoplasms (40)  ·  Stomach Neoplasms (38)  ·  Carcinoma, Intraductal, Noninfiltrating (35)

Broader conditions

Skin Diseases (2189)  ·  Skin and Connective Tissue Diseases (2189)  ·  Neoplasms by Site (2186)  ·  Breast Diseases (2183)  ·  Neoplasms (2113)  ·  Pathological Conditions, Signs and Symptoms (232)  ·  Neoplasms by Histologic Type (184)  ·  Pathologic Processes (182)  ·  Urogenital Diseases (155)  ·  Urogenital Neoplasms (149)  ·  Neoplasms, Glandular and Epithelial (144)  ·  Genital Diseases (141)  ·  Carcinoma (131)  ·  Female Urogenital Diseases (131)  ·  Female Urogenital Diseases and Pregnancy Complications (131)

Interventions

Trastuzumab (248)  ·  Cyclophosphamide (226)  ·  Docetaxel (199)  ·  Paclitaxel (197)  ·  Capecitabine (133)  ·  Carboplatin (130)  ·  Doxorubicin (127)  ·  Letrozole (127)  ·  Fulvestrant (92)  ·  Bevacizumab (82)  ·  Anastrozole (74)  ·  Epirubicin (73)  ·  Tamoxifen (69)  ·  Gemcitabine (65)  ·  pertuzumab (62)

Sponsors

Fudan University (57)  ·  Memorial Sloan Kettering Cancer Center (54)  ·  Hoffmann-La Roche (48)  ·  Dana-Farber Cancer Institute (47)  ·  M.D. Anderson Cancer Center (43)  ·  National Cancer Institute (NCI) (38)  ·  Alliance for Clinical Trials in Oncology (30)  ·  Eli Lilly and Company (27)  ·  AstraZeneca (21)  ·  SCRI Development Innovations, LLC (20)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (20)  ·  UNC Lineberger Comprehensive Cancer Center (20)  ·  Novartis Pharmaceuticals (18)  ·  Sun Yat-sen University (18)  ·  H. Lee Moffitt Cancer Center and Research Institute (17)

Countries

United States (1115)  ·  China (292)  ·  Spain (165)  ·  France (146)  ·  Canada (129)  ·  United Kingdom (120)  ·  Italy (113)  ·  Germany (97)  ·  Belgium (91)  ·  South Korea (79)  ·  Australia (62)  ·  Netherlands (49)  ·  Brazil (43)  ·  Taiwan (42)  ·  Singapore (40)

Top investigators

Mothaffar Rimawi, MD (12)  ·  Denise A. Yardley, MD (10)  ·  Edith A. Perez, MD (10)  ·  Norman Wolmark, MD (9)  ·  Dimitris Mavrudis, MD (8)  ·  Hope S. Rugo, MD (8)  ·  Sara Tolaney, MD, MPH (8)  ·  William J. Gradishar, MD (8)

Results publications

PMID 34037241, PMID 38979716, PMID 33736679, PMID 12473512, PMID 21730275, PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 23044556, PMID 24327334, PMID 28057664, PMID 29530935, PMID 30627694, PMID 31615937, PMID 31838010, PMID 32001832, PMID 32053137, PMID 32450725, PMID 32880602, PMID 33084020, PMID 33138866, PMID 35537408, PMID 38745646, PMID 40443562, PMID 42334791, PMID 10080589, PMID 10210538, PMID 10227040, PMID 10561296, PMID 10574414, PMID 10628376, PMID 10766175, PMID 10964265, PMID 11160563, PMID 11206194, PMID 11230490, PMID 11352950, PMID 11516635, PMID 11530286, PMID 11745247, PMID 11815400, PMID 11882333, PMID 11893482, PMID 11999415, PMID 12006121, PMID 12138395, PMID 12196717, PMID 12533263, PMID 12610186

NIH funding

2023 (21), 2008 (16), 2014 (15), 2016 (14), 2009 (10), 2018 (10), 2019 (10), P30CA006973 (10), 2025 (9), P30CA033572 (9), P30CA043703 (9), U10CA032102 (9), 2017 (8), 2015 (7), P30CA072720 (7)